Hoping to continue the success of its blockbuster antipsychotic drug, Zyprexa, Eli Lilly has suffered a setback in its request for FDA approval of a longer-lasting formulation. Zyprexa is mired in controversy about the side effects and allegations that Lilly withheld important safety information.